Women diagnosed with HER2+ breast cancer are candidates for monoclonal antibody (mAb) therapies that interfere with HER2 by binding to its extracellular domains, including Trastuzumab (Herceptin) and Pertuzumab (Perjeta), as well as tyrosine kinase inhibitors (TKIs) such as Lapatinib, Neratinib and Tucatinib20–23. Here, ERBB2 is linked to breast cancer.